b'<?xml version="1.0" ?>\n<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">\n<PubmedArticleSet>\n<PubmedArticle>\n    <MedlineCitation Status="MEDLINE" Owner="NLM">\n        <PMID Version="1">30681186</PMID>\n        <DateCompleted>\n            <Year>2019</Year>\n            <Month>12</Month>\n            <Day>20</Day>\n        </DateCompleted>\n        <DateRevised>\n            <Year>2019</Year>\n            <Month>12</Month>\n            <Day>20</Day>\n        </DateRevised>\n        <Article PubModel="Print-Electronic">\n            <Journal>\n                <ISSN IssnType="Electronic">1531-8257</ISSN>\n                <JournalIssue CitedMedium="Internet">\n                    <Volume>34</Volume>\n                    <Issue>3</Issue>\n                    <PubDate>\n                        <Year>2019</Year>\n                        <Month>03</Month>\n                    </PubDate>\n                </JournalIssue>\n                <Title>Movement disorders : official journal of the Movement Disorder Society</Title>\n                <ISOAbbreviation>Mov. Disord.</ISOAbbreviation>\n            </Journal>\n            <ArticleTitle>Effects of subthalamic nucleus stimulation and levodopa on decision-making in Parkinson\'s disease.</ArticleTitle>\n            <Pagination>\n                <MedlinePgn>377-385</MedlinePgn>\n            </Pagination>\n            <ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.27625</ELocationID>\n            <Abstract>\n                <AbstractText Label="BACKGROUND">Parkinson\'s disease (PD) is frequently associated with behavioral disorders, particularly within the spectrum of motivated behaviors such as apathy or impulsivity. Both pharmacological and neurosurgical treatments have an impact on these impairments. However, there still is controversy as to whether subthalamic nucleus deep brain stimulation (STN-DBS) can cause or reduce impulsive behaviors.</AbstractText>\n                <AbstractText Label="OBJECTIVES">We aimed to identify the influence of functional surgery on decision-making processes in PD.</AbstractText>\n                <AbstractText Label="METHODS">We studied 13 PD patients and 13 healthy controls. The experimental task involved squeezing a dynamometer with variable force to obtain rewards of various values under four conditions: without treatment, with l-dopa or subthalamic stimulation alone, and with both l-dopa and subthalamic stimulation. Statistical analyses consisted of generalized linear mixed models including treatment condition, reward value, level of effort, and their interactions. We analyzed acceptance rate (the percentage of accepted trials), decision time, and force applied.</AbstractText>\n                <AbstractText Label="RESULTS">Comparatively to controls, patients without treatment exhibited lower acceptance rate and force applied. Patients under l-dopa alone did not exhibit increased acceptance rate. With subthalamic stimulation, either with or without added l-dopa, all measures were improved so that patients\' behaviors were undistinguishable from healthy controls\'.</AbstractText>\n                <AbstractText Label="CONCLUSIONS">Our study shows that l-dopa administration does not fully restore cost-benefit decision-making processes, whereas STN-DBS fully normalizes patients\' behaviors. These findings suggest that dopamine is partly involved in cost-benefit valuation, and that STN-DBS can have a beneficial effect on motivated behaviors in PD and may improve certain forms of impulsive behaviors. \xc2\xa9 2019 International Parkinson and Movement Disorder Society.</AbstractText>\n                <CopyrightInformation>\xc2\xa9 2019 International Parkinson and Movement Disorder Society.</CopyrightInformation>\n            </Abstract>\n            <AuthorList CompleteYN="Y">\n                <Author ValidYN="Y">\n                    <LastName>Atkinson-Clement</LastName>\n                    <ForeName>Cyril</ForeName>\n                    <Initials>C</Initials>\n                    <Identifier Source="ORCID">0000-0001-9499-3485</Identifier>\n                    <AffiliationInfo>\n                        <Affiliation>Aix Marseille Universit\xc3\xa9, CNRS, LPL, Aix-en-Provence, France.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Aix Marseille Universit\xc3\xa9, CNRS, INT, Inst Neurosci Timone, Marseille, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Cavazzini</LastName>\n                    <ForeName>\xc3\x89milie</ForeName>\n                    <Initials>\xc3\x89</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Aix Marseille Universit\xc3\xa9, CNRS, LPL, Aix-en-Provence, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Z\xc3\xa9non</LastName>\n                    <ForeName>Alexandre</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Institute of Neuroscience, Universit\xc3\xa9 Catholique de Louvain, Brussels, Belgium.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>INCIA, Universit\xc3\xa9 de Bordeaux, CNRS UMR5287, Bordeaux, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Witjas</LastName>\n                    <ForeName>Tatiana</ForeName>\n                    <Initials>T</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Aix Marseille Universit\xc3\xa9, CNRS, INT, Inst Neurosci Timone, Marseille, France.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Aix Marseille Universit\xc3\xa9, APHM, CHU Timone, Department of Neurology and Movement Disorders, Marseille, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Fluch\xc3\xa8re</LastName>\n                    <ForeName>Fr\xc3\xa9d\xc3\xa9rique</ForeName>\n                    <Initials>F</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Aix Marseille Universit\xc3\xa9, APHM, CHU Timone, Department of Neurology and Movement Disorders, Marseille, France.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Aix Marseille Universit\xc3\xa9, CNRS, LNC, Marseille, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Azulay</LastName>\n                    <ForeName>Jean-Philippe</ForeName>\n                    <Initials>JP</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Aix Marseille Universit\xc3\xa9, CNRS, INT, Inst Neurosci Timone, Marseille, France.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Aix Marseille Universit\xc3\xa9, APHM, CHU Timone, Department of Neurology and Movement Disorders, Marseille, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Baunez</LastName>\n                    <ForeName>Christelle</ForeName>\n                    <Initials>C</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Aix Marseille Universit\xc3\xa9, CNRS, INT, Inst Neurosci Timone, Marseille, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n                <Author ValidYN="Y">\n                    <LastName>Eusebio</LastName>\n                    <ForeName>Alexandre</ForeName>\n                    <Initials>A</Initials>\n                    <AffiliationInfo>\n                        <Affiliation>Aix Marseille Universit\xc3\xa9, CNRS, INT, Inst Neurosci Timone, Marseille, France.</Affiliation>\n                    </AffiliationInfo>\n                    <AffiliationInfo>\n                        <Affiliation>Aix Marseille Universit\xc3\xa9, APHM, CHU Timone, Department of Neurology and Movement Disorders, Marseille, France.</Affiliation>\n                    </AffiliationInfo>\n                </Author>\n            </AuthorList>\n            <Language>eng</Language>\n            <GrantList CompleteYN="Y">\n                <Grant>\n                    <GrantID>ANR-09-MNPS-028-01</GrantID>\n                    <Agency>Agence Nationale de la Recherche</Agency>\n                    <Country>International</Country>\n                </Grant>\n                <Grant>\n                    <Agency>PACA Regional Council and Orthomalin</Agency>\n                    <Country>International</Country>\n                </Grant>\n            </GrantList>\n            <PublicationTypeList>\n                <PublicationType UI="D016428">Journal Article</PublicationType>\n                <PublicationType UI="D013485">Research Support, Non-U.S. Gov\'t</PublicationType>\n            </PublicationTypeList>\n            <ArticleDate DateType="Electronic">\n                <Year>2019</Year>\n                <Month>01</Month>\n                <Day>25</Day>\n            </ArticleDate>\n        </Article>\n        <MedlineJournalInfo>\n            <Country>United States</Country>\n            <MedlineTA>Mov Disord</MedlineTA>\n            <NlmUniqueID>8610688</NlmUniqueID>\n            <ISSNLinking>0885-3185</ISSNLinking>\n        </MedlineJournalInfo>\n        <ChemicalList>\n            <Chemical>\n                <RegistryNumber>0</RegistryNumber>\n                <NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance>\n            </Chemical>\n            <Chemical>\n                <RegistryNumber>46627O600J</RegistryNumber>\n                <NameOfSubstance UI="D007980">Levodopa</NameOfSubstance>\n            </Chemical>\n        </ChemicalList>\n        <CitationSubset>IM</CitationSubset>\n        <MeshHeadingList>\n            <MeshHeading>\n                <DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName>\n                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>\n                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D003071" MajorTopicYN="N">Cognition</DescriptorName>\n                <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>\n                <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D003657" MajorTopicYN="N">Decision Making</DescriptorName>\n                <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>\n                <QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D046690" MajorTopicYN="N">Deep Brain Stimulation</DescriptorName>\n                <QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName>\n                <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>\n                <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D009483" MajorTopicYN="N">Neuropsychological Tests</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName>\n                <QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>\n                <QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName>\n                <QualifierName UI="Q000523" MajorTopicYN="N">psychology</QualifierName>\n                <QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D011788" MajorTopicYN="N">Quality of Life</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D012201" MajorTopicYN="N">Reward</DescriptorName>\n            </MeshHeading>\n            <MeshHeading>\n                <DescriptorName UI="D020531" MajorTopicYN="N">Subthalamic Nucleus</DescriptorName>\n                <QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName>\n            </MeshHeading>\n        </MeshHeadingList>\n        <KeywordList Owner="NOTNLM">\n            <Keyword MajorTopicYN="Y">basal ganglia</Keyword>\n            <Keyword MajorTopicYN="Y">cost-benefit</Keyword>\n            <Keyword MajorTopicYN="Y">deep brain stimulation</Keyword>\n            <Keyword MajorTopicYN="Y">dopamine</Keyword>\n            <Keyword MajorTopicYN="Y">effort</Keyword>\n        </KeywordList>\n    </MedlineCitation>\n    <PubmedData>\n        <History>\n            <PubMedPubDate PubStatus="received">\n                <Year>2018</Year>\n                <Month>06</Month>\n                <Day>11</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="revised">\n                <Year>2018</Year>\n                <Month>10</Month>\n                <Day>26</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="accepted">\n                <Year>2018</Year>\n                <Month>11</Month>\n                <Day>30</Day>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="pubmed">\n                <Year>2019</Year>\n                <Month>1</Month>\n                <Day>27</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="medline">\n                <Year>2019</Year>\n                <Month>12</Month>\n                <Day>21</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n            <PubMedPubDate PubStatus="entrez">\n                <Year>2019</Year>\n                <Month>1</Month>\n                <Day>26</Day>\n                <Hour>6</Hour>\n                <Minute>0</Minute>\n            </PubMedPubDate>\n        </History>\n        <PublicationStatus>ppublish</PublicationStatus>\n        <ArticleIdList>\n            <ArticleId IdType="pubmed">30681186</ArticleId>\n            <ArticleId IdType="doi">10.1002/mds.27625</ArticleId>\n        </ArticleIdList>\n    </PubmedData>\n</PubmedArticle>\n\n</PubmedArticleSet>'